Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

NASH is becoming a leading indication for liver transplants in patients with hepatocellular carcinoma

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the USA, reports this month's issue of Hepatology.

News image

Nonalcoholic steatohepatitis (NASH) is currently the third leading indication for liver transplantation in the U.S. and is predicted to become the leading indication for liver transplantation in the near future.

The trends in NASH-related hepatocellular carcinoma (HCC) among liver transplantation recipients in the U.S. remain undefined.

Dr Aijaz Ahmed and colleagues from California, USA performed a retrospective cohort study to evaluate trends in the etiology of HCC among adult liver transplantation recipients in the U.S. from 2002 to 2012, using national data from the United Network for Organ Sharing registry.

From 2002-2012, there were 61,868 adults who underwent liver transplantation in the U.S., including 10,061 patients with HCC.

NASH is the second leading etiology of HCC-related liver transplantation
Hepatology

The team noted that the total number and proportion of HCC liver transplant recipients demonstrated a significant increase following the implementation of the Model for Endstage Liver Disease (MELD) scoring system in 2002.

The researchers observed that the proportion of hepatitis C virus (HCV)-related HCC increased steadily from 2002 to 2012, and HCV remained the leading etiology of HCC throughout the MELD era.

The team found that NASH-related HCC also increased significantly, and NASH is the second leading etiology of HCC-related liver transplantation.

From 2002 to 2012, the number of patients undergoing liver transplantation for HCC secondary to NASH increased by nearly 4-fold, and the number of liver transplantation patients with HCC secondary to HCV increased by 2-fold.

Dr Ahmed's team comments, "NASH is the second leading etiology of HCC leading to liver transplantation in the U.S."

"More important, NASH is currently the most rapidly growing indication for liver transplantation in patients with HCC in the U.S."

Hepatology 2014: 59(6): 2188–2195
17 June 2014

Go to top of page Email this page Email this page to a colleague

 23 August 2014

Advanced search
 22 August 2014 
Endoscopic submucosal dissection for squamous esophageal cancer
 22 August 2014 
Adherence to Rome criteria in functional dyspepsia trials
 22 August 2014 
Outlier identification in colorectal surgery
 21 August 2014 
Screening for Barrett’s esophagus
 21 August 2014 
Colorectal cancer mortality in Brazil
 21 August 2014 
Eosinophilic esophagitis
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 19 August 2014 
Variability of colonoscopy preparation instructions
 18 August 2014 
The evolution of urban C. difficile
 18 August 2014 
Metabolomic analysis in IBD
 18 August 2014 
Enhanced T-cell response in acute-on-chronic Hep B
 15 August 2014 
Abdominal pain in IBS
 15 August 2014 
Gene expression biomarker in ulcerative colitis
 15 August 2014 
Population-based fecal immunochemical test screening
 14 August 2014 
Transnasal vs transoral endoscopy
 14 August 2014 
Radiation exposure in gastroenterology
 14 August 2014 
Dietary fibre and diverticular disease
 13 August 2014 
Flexible sigmoidoscopy screening
 13 August 2014 
Adherence to Rome criteria in functional dyspepsia
 13 August 2014 
Fecal immunochemical test screening
 12 August 2014 
Eosinophilic esophagitis and celiac disease
 12 August 2014 
Management of Lynch syndrome
 12 August 2014 
Risk of cancer under immunosuppressive therapy in IBD
 11 August 2014 
Risk of GI bleeds with anticoagulants
 11 August 2014 
Social media in health-care
 11 August 2014 
Gut microbiota in chemotherapy-induced GI mucositis
 08 August 2014 
Endoscopy nurse-administered propofol sedation performance
 08 August 2014 
Therapy for biliary tract cancer
 08 August 2014 
Surgeon volume and esophagectomy survival
 07 August 2014 
Global consensus on perianal fistulizing Crohn's disease
 07 August 2014 
Smoking cessation and age of onset of ulcerative colitis
 07 August 2014 
Colonoscopy length and training duration
 06 August 2014 
Hepatitis C virus infection in the United States
 06 August 2014 
Pediatric to adult IBD care
 06 August 2014 
Biomarker of disease activity in IBD
 05 August 2014 
Rising incidence of celiac disease
 05 August 2014 
Socioeconomic status and IBS
 05 August 2014 
Bowel dysfunction after sphincter-preserving rectal cancer surgery
 04 August 2014 
Relative adrenal insufficiency and chronic liver disease
 04 August 2014 
Colonoscopy screening protocol for liver transplant recipients
 04 August 2014 
Patient-reported outcomes after upper GI bleed
 01 August 2014 
Capsule colonoscopy vs CT colonography for polyp screening
 01 August 2014 
Complications after obesity surgery
 01 August 2014 
Fully covered self-expanding metal stents for benign biliary strictures
 31 July 2014 
Biomarkers in liver fibrosis
 31 July 2014 
Risk factors of large colorectal polyps
 31 July 2014 
Diverticular disease and colon cancer
 30 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 30 July 2014 
Mineral rich water and constipation
 30 July 2014 
Interval between screening colonoscopies
 29 July 2014 
Fluticasone in eosinophilic esophagitis
 29 July 2014 
Causes of GI bleeding in cirrhosis
 29 July 2014 
ALT increases in Hep B
 28 July 2014 
Statins reduce Barrett's
 28 July 2014 
Score predicts risk for Barrett’s esophagus
 28 July 2014 
Gastric cancer prevention

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us